Dimerix (ASX: DXB) Acquires Phase 2 Kidney Disease Asset Targeting US$3.5 Billion Market

Dimerix (ASX: DXB) has taken a significant step toward becoming a broader kidney disease specialist, announcing the acquisition of Phase 2-ready drug candidate DMX-652, a potential treatment for acute kidney injury (AKI), a condition with no approved therapies and an estimated global market opportunity of US$3.5 billion in 2026.

The announcement marks more than just a pipeline expansion. It shifts Dimerix from being largely centred on a single late-stage drug candidate to a company developing multiple clinical-stage therapies targeting kidney disease.

DMX-652 arrives with several key development milestones already completed. The asset has an open US Food and Drug Administration (FDA) Investigational New Drug application, an FDA-cleared Phase 2 clinical trial protocol, completed GMP manufacturing and patent protection expected through to 2041. Together, these factors could allow Dimerix to move into Phase 2 testing more quickly than if it were developing an early-stage compound from scratch.

Live stock: Source Tradingview

The company also highlighted encouraging early clinical data. A Phase 1 trial involving 85 healthy participants found DMX-652 was well tolerated following both single and multiple doses over 14 days, with no serious adverse events related to the treatment.

The acquisition complements Dimerix’s lead candidate, DMX-200, which is currently being evaluated in the Phase 3 ACTION3 trial for focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

For biotechnology companies, diversification can be important. Investors often view businesses with multiple clinical programs more favourably because they reduce reliance on the success of a single therapy while creating additional opportunities for partnerships, licensing and future commercialisation.

Acute kidney injury also represents a substantial unmet medical need. The condition involves a sudden loss of kidney function and is associated with high mortality rates. According to Dimerix, there are currently no approved treatments, while the addressable patient population in the United States alone is estimated at between 100,000 and 133,000 patients each year. The company believes the global market could grow from US$3.5 billion in 2026 to around US$7.5 billion over the coming decade. (Source: Dimerix ASX announcement.)

The acquisition also arrives alongside measures designed to strengthen Dimerix’s financial position. The company announced a A$10 million non-dilutive loan facility, approximately A$14 million in upfront proceeds from Everest Medicines, existing cash reserves and ongoing discussions for an additional A$40 million in non-dilutive funding.

Management said these funding sources are expected to support completion of the ACTION3 Phase 3 trial while also allowing DMX-652 to advance into Phase 2 without the need for an immediate capital raising.

Chief Executive Officer and Managing Director Dr Nina Webster said the acquisition fits closely with the company’s long-term strategy.

“DMX-652 represents an exciting and differentiated novel compound, and the acquisition of a Phase 2-ready program in acute kidney disease represents an important step in executing our strategy to expand our renal pipeline. This asset is highly complementary to our Phase 3 FSGS program and broadens our development footprint across the kidney disease continuum, from acute injury through to chronic disease.”

On funding, Dr Webster added:

“To ensure Dimerix is well positioned to execute on the significant opportunity in acute kidney injury with DMX-652 and to prepare for commercial success of our lead asset, DMX-200, we have taken steps to boost our balance sheet with this non-dilutive cash injection to take us through to completion of the ACTION3 Phase 3 trial in DMX-200, as well as initiation of the Phase 2 clinical trial in DMX-652.”

“This loan facility agreement delivers funding at a substantially lower cost of capital than other sources and on terms that the Dimerix Board believe are firmly aligned with company and shareholder interests.”

The broader kidney disease sector continues to attract growing attention from pharmaceutical companies, particularly therapies addressing orphan diseases and conditions with few or no approved treatments. These markets can offer faster regulatory pathways, premium pricing and extended market exclusivity if successful.

For Dimerix, the acquisition creates several potential milestones over the next two years, including the commencement of a Phase 2 trial for DMX-652, further progress in the ACTION3 Phase 3 study, possible orphan drug designation and additional partnership opportunities.

While DMX-652 must still demonstrate clinical effectiveness in Phase 2, the acquisition significantly broadens Dimerix’s pipeline and strengthens its position as a company building a diversified portfolio of kidney disease therapies rather than relying on a single late-stage asset.